EGTX Stock Analysis: Egetis Therapeutics (publ) | ST
Biotechnology | ST, Sweden | Market Cap: 5.170m SEK | 12M Return: 79.1% | SE0003815604 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 17.7M
Qual. Beats: 0
Rev. Trend: 37.2%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Egetis Therapeutics is a Sweden-based biotechnology company focused on developing and commercializing orphan drugs. Its clinical-stage pipeline includes Aladote for paracetamol poisoning and Emcitate for MCT8 deficiency.
Biotechnology companies typically advance drug candidates through clinical trials and regulatory review before potential commercialization. Egetis, headquartered in Stockholm, was incorporated in 2006 and changed its name from PledPharma in 2020.
- EU-approved Emcitate uptake and U.S. review drive revenue prospects
- Aladote trial results determine pipeline value and future regulatory potential
- Commercial launch costs and cash burn raise funding and dilution risk
| Net Income: -405.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.40 > 0.02 and ΔFCF/TA -2.52 > 1.0 |
| NWC/Revenue: 196.7% < 20% (prev 41.56%; Δ 155.1% < -1%) |
| CFO/TA -0.39 > 3% & CFO -300.3m > Net Income -405.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (448.9m) vs 12m ago 24.80% < -2% |
| Gross Margin: 16.79% > 18% (prev 39.87%; Δ -23.08% > 0.5%) |
| Asset Turnover: 9.34% > 50% (prev 7.24%; Δ 2.10% > 0%) |
| Interest Coverage Ratio: -20.96 > 6 (EBIT TTM -387.8m / Interest Expense TTM 18.5m) |
| A: 0.17 (Total Current Assets 396.7m - Total Current Liabilities 266.7m) / Total Assets 760.5m |
| B: -2.83 (Retained Earnings -2.15b / Total Assets 760.5m) |
| C: -0.55 (EBIT TTM -387.8m / Avg Total Assets 707.5m) |
| D: 1.73 (Book Value of Equity 481.5m / Total Liabilities 278.9m) |
| Altman-Z'' = -9.97 = D |
| DSRI: 0.19 (Receivables 11.0m/42.3m, Revenue 66.1m/47.4m) |
| GMI: 2.37 (GM 39.87% / 16.79%) |
| AQI: 0.77 (AQ_t 0.47 / AQ_t-1 0.61) |
| SGI: 1.39 (Revenue 66.1m / 47.4m) |
| TATA: -0.14 (NI -405.5m - CFO -300.3m) / TA 760.5m) |
| Beneish M = -2.32 (Cap -4..+1) = BBB |
As of November 06, 2026, the stock is trading at SEK 11.12 with a total of 33,187,786 shares traded. Over the past week, the price has changed by +7.54%, over one month by +22.74%, over three months by +64.99% and over the past year by +79.07%.
Current recommended Stop Loss: 10.60 (which is 4.7% or 1.1 ATR below the current price).
Egetis Therapeutics (publ) has no consensus analysts rating.
P/E Forward = 8.7796
P/S = 78.3397
P/B = 9.6027
Revenue TTM = 66.1m SEK
EBIT TTM = -387.8m SEK
EBITDA TTM = -384.1m SEK
Long Term Debt = 45.0m SEK (from longTermDebt, last fiscal year)
Short Term Debt = 64.7m SEK (from shortTermDebt, last quarter)
Debt = 82.9m SEK (from shortLongTermDebtTotal, last quarter) + Leases 14.1m
Net Debt = -295.5m SEK (calculated: Debt 82.9m - CCE 378.4m)
Enterprise Value = 4.87b SEK (5.17b + Debt 82.9m - CCE 378.4m)
Interest Coverage Ratio = -20.96 (Ebit TTM -387.8m / Interest Expense TTM 18.5m)
EV/FCF = -16.18x (Enterprise Value 4.87b / FCF TTM -301.3m)
FCF Yield = -6.18% (FCF TTM -301.3m / Enterprise Value 4.87b)
FCF Margin = -455.8% (FCF TTM -301.3m / Revenue TTM 66.1m)
Net Margin = -613.5% (Net Income TTM -405.5m / Revenue TTM 66.1m)
Gross Margin = 16.79% ((Revenue TTM 66.1m - Cost of Revenue TTM 55.0m) / Revenue TTM)
Gross Margin QoQ = 20.69% (prev -1.49%)
Tobins Q-Ratio = 6.41 (Enterprise Value 4.87b / Total Assets 760.5m)
Interest Expense / Debt = 22.32% (Interest Expense 18.5m / Debt 82.9m)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -290.9m (EBIT -387.8m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.49 (Total Current Assets 396.7m / Total Current Liabilities 266.7m)
Debt / Equity = 0.17 (Debt 82.9m / totalStockholderEquity, last quarter 481.5m)
Debt / EBITDA = 0.77 (negative EBITDA) (Net Debt -295.5m / EBITDA -384.1m)
Debt / FCF = 0.98 (negative FCF - burning cash) (Net Debt -295.5m / FCF TTM -301.3m)
Total Stockholder Equity = 336.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -57.32% (Net Income -405.5m / Total Assets 760.5m)
RoE = -120.5% (Net Income TTM -405.5m / Total Stockholder Equity 336.6m)
RoCE = -101.6% (out of range, set to none) (EBIT -387.8m / Capital Employed (Equity 336.6m + L.T.Debt 45.0m))
RoIC = -52.39% (negative operating profit) (NOPAT -290.9m / Invested Capital 555.2m)
WACC = 8.20% (E(5.17b)/V(5.25b) * Re(8.06%) + D(82.9m)/V(5.25b) * Rd(22.32%) * (1-Tc(0.25)))
Discount Rate = 8.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.06 | Cagr: 20.96%
[DCF] Fair Price = unknown (Cash Flow -301.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.47 | # QB: 0
Revenue Correlation: 37.20 | Revenue CAGR: 10.33% | SUE: -0.53 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.20 | Chg30d=+6.38% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.46 | Chg30d=+152.89% | Revisions=+25% | GrowthEPS=+151.1% | GrowthRev=+761.6%
EPS next Year (2027-12-31): EPS=-0.22 | Chg30d=+52.02% | Revisions=+17% | GrowthEPS=-147.5% | GrowthRev=-5.1%
[Analyst] Revisions Ratio: +38% (up=4, down=1)